Failure of vitamin B6 to reverse the l-dopa effect in patients on a dopa decarboxylase inhibitor
AUTOR(ES)
Klawans, Harold L.
RESUMO
Seven patients with Parkinsonism previously on l-dopa were placed on a regimen of l-dopa and alpha methyl dopa hydrazine (a dopa decarboxylase inhibitor). Two of these patients had previously shown marked clinical deterioration of the l-dopa improvement when given pyridoxine. None of the seven patients receiving alpha methyl dopa hydrazine demonstrated any change in their condition when given pyridoxine. The failure of vitamin B6 to reverse the clinical effect of l-dopa in patients receiving both l-dopa and a peripheral dopa decarboxylase inhibitor suggests that reversal of the l-dopa effect induced by vitamin B6 is due to increasing the activity of the enzyme dopa decarboxylase outside the central nervous system.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1083502Documentos Relacionados
- Modification of the cardiovascular effects of l-dopa by decarboxylase inhibitors
- Effects of L-Dopa on Norepinephrine Metabolism in the Brain
- Interactions of L-dopa and amantadine in patients with Parkinsonism
- L-dopa and arousal 1
- Decrease in Liver Aromatic L-Amino-Acid Decarboxylase Produced by Chronic Administration of L-Dopa